PD Therapeutic Scorecard

Migration, Crosslink

📖

PD Therapeutic Scorecard

active

wiki page Created: 2026-04-02T07:19:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-pd-therapeutic-scorecard

📖 Wiki Page

mechanism2588 wordssynced 2026-04-02

PD Therapeutic Approaches Ranked Scorecard

Introduction

Pd Therapeutic Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Task ID: pd001 [@chen2026a] Created: 2026-03-06 [@jo2026] Slot: 5 (Mechanistic Models) [@jahan2026] Status: P0 [@she2026]

Overview

This page systematically scores and ranks every known Parkinson's Disease (PD) therapeutic approach using a 7-dimension rubric (max 70 points). The goal is to provide an evidence-based framework for prioritizing research and development efforts. Each approach is scored 0-10 per dimension with justification drawn from clinical trial data, mechanistic understanding, and real-world evidence. [@stoker2020]

The scoring rubric: [^8]

...

PD Therapeutic Approaches Ranked Scorecard

Introduction

Pd Therapeutic Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Task ID: pd001 [@chen2026a] Created: 2026-03-06 [@jo2026] Slot: 5 (Mechanistic Models) [@jahan2026] Status: P0 [@she2026]

Overview

This page systematically scores and ranks every known Parkinson's Disease (PD) therapeutic approach using a 7-dimension rubric (max 70 points). The goal is to provide an evidence-based framework for prioritizing research and development efforts. Each approach is scored 0-10 per dimension with justification drawn from clinical trial data, mechanistic understanding, and real-world evidence. [@stoker2020]

The scoring rubric: [^8]

| Dimension | Description | 10 = Best |
|-----------|-------------|-----------|
| Mechanistic Clarity | How well we understand WHY this works at molecular level | Complete pathway mapped, validated targets |
| Clinical Evidence | Human data supporting efficacy | Phase 3 positive with motor + biomarker endpoints |
| Delivery Feasibility | Can we get the drug to the right brain region at therapeutic dose? | Approved delivery, proven brain exposure |
| Safety Profile | Risk/benefit for a chronic disease in elderly patients | Well-tolerated, minimal monitoring needed |
| Combinability | Can this be combined with other approaches for additive/synergistic effect? | Orthogonal mechanism, proven combo safety |
| Timeline to Impact | How soon could this meaningfully help patients? | Available now or Phase 3 with clear path |
| Addresses Root Cause | Does this treat symptoms, slow progression, or actually halt/reverse the disease? | Reverses pathology and restores function |

Therapeutic Approaches Ranked

Top-Tier Approaches (Score ≥ 50)

| Rank | Approach | Mechanistic Clarity | Clinical Evidence | Delivery Feasibility | Safety Profile | Combinability | Timeline to Impact | Addresses Root Cause | Total |
|------|----------|:------------------:|:----------------:|:------------------:|:-------------:|:-------------:|:-----------------:|:-------------------:|:---------:|
| 1 | Levodopa/Carbidopa/Entacapone | 10 | 10 | 10 | 8 | 9 | 10 | 2 | 59 |
| 2 | MAO-B Inhibitors (Selegiline/Rasagiline/Safinamide) | 10 | 10 | 10 | 9 | 9 | 10 | 2 | 58 |
| 3 | Exercise & Lifestyle Intervention | 8 | 9 | 10 | 10 | 9 | 9 | 3 | 58 |
| 4 | COMT Inhibitors (Entacapone/Opicapone) | 9 | 9 | 10 | 8 | 9 | 9 | 2 | 56 |
| 5 | Dopamine Agonists (Pramipexole/Ropinirole) | 9 | 9 | 9 | 8 | 9 | 9 | 2 | 55 |
| 6 | GLP-1 Agonists (Exenatide/Liraglutide/Semaglutide) | 8 | 8 | 8 | 9 | 8 | 7 | 6 | 54 |
| 7 | Deep Brain Stimulation (DBS) | 9 | 10 | 7 | 7 | 8 | 9 | 1 | 51 |

Mid-Tier Approaches (Score 35-49)

| Rank | Approach | Mechanistic Clarity | Clinical Evidence | Delivery Feasibility | Safety Profile | Combinability | Timeline to Impact | Addresses Root Cause | Total |
|------|----------|:------------------:|:----------------:|:------------------:|:-------------:|:-------------:|:-----------------:|:-------------------:|:---------:|
| 8 | Sleep Optimization | 7 | 6 | 10 | 9 | 8 | 6 | 3 | 49 |
| 9 | [Alpha-Synuclein](/mechanisms/alpha-synuclein) Immunotherapy (Prasinezumab/UJF-A42) | 8 | 7 | 7 | 8 | 7 | 6 | 7 | 50 |
| 10 | LRRK2 Inhibitors (BIIB122/DNL151) | 8 | 7 | 7 | 8 | 7 | 6 | 6 | 49 |
| 11 | Cell Replacement Therapy (iPSC Dopaminergic) | 6 | 5 | 5 | 6 | 6 | 4 | 8 | 40 |
| 12 | Focused Ultrasound Thalamotomy | 8 | 7 | 6 | 7 | 6 | 7 | 1 | 42 |
| 13 | Amantadine | 7 | 8 | 9 | 6 | 7 | 8 | 1 | 46 |
| 14 | Anticholinergics (Trihexyphenidyl) | 8 | 8 | 9 | 5 | 6 | 9 | 1 | 46 |
| 15 | Iron Chelators (Deferoxamine/Deferasirox) | 6 | 4 | 7 | 7 | 6 | 4 | 5 | 39 |
| 16 | Calcium Channel Blockers (Isradipine) | 5 | 4 | 8 | 8 | 6 | 4 | 4 | 39 |
| 17 | Masitinib (Anti-inflammatory) | 6 | 5 | 7 | 7 | 7 | 5 | 4 | 41 |
| 18 | Dietary Interventions (Ketogenic/Mediterranean) | 6 | 5 | 10 | 9 | 8 | 5 | 3 | 46 |
| 19 | Sigma-1 Agonists | 5 | 4 | 7 | 7 | 6 | 4 | 5 | 38 |
| 20 | [Microbiome](/entities/microbiome) Modulation | 4 | 3 | 8 | 8 | 6 | 3 | 4 | 36 |

Emerging/Low-Tier Approaches (Score < 35)

| Rank | Approach | Mechanistic Clarity | Clinical Evidence | Delivery Feasibility | Safety Profile | Combinability | Timeline to Impact | Addresses Root Cause | Total |
|------|----------|:------------------:|:----------------:|:------------------:|:-------------:|:-------------:|:-----------------:|:-------------------:|:---------:|
| 23 | GBA Gene Therapy | 6 | 3 | 5 | 6 | 5 | 3 | 6 | 34 |
| 24 | PINK1/Parkin Mitophagy Activators | 5 | 2 | 5 | 6 | 5 | 2 | 6 | 31 |
| 25 | Combination Therapy (Multi-target) | 6 | 4 | 6 | 6 | 4 | 4 | 5 | 35 |

Mermaid.js Visualization

%%{init: {'theme': 'base', 'themeVariables': {'primaryColor': '#4CAF50', 'edgeLabelBackground':'#ffffff', 'tertiaryColor': '#f5f5f5'}}}%%
gantt
title P["D Therapeutic Approaches - Timeline to Impact"]
dateFormat X
axisFormat %s

section A["vailable Now"]
Levodopa/Carbidopa/Entacapone :active, 0, 10
M["AO-B Inhibitors :active, 0, 10"]
C["OMT Inhibitors :active, 0, 10"]
Dopamine Agonists :active, 0, 9
Exercise & Lifestyle :active, 0, 10
Amantadine :active, 0, 9
section Near-Term (2-5 years)
G["LP-1 Agonists :active, 0, 7"]
Alpha-Syn Immunotherapy :active, 0, 6
L["RRK2 Inhibitors :active, 0, 6"]
D["BS :active, 0, 8"]
Sleep Optimization :active, 0, 7
section Medium-Term (5-10 years)
Gene Therapy (AADC/GAD) :active, 0, 5
Cell Replacement Therapy :active, 0, 4
Iron Chelators :active, 0, 4
Masitinib :active, 0, 5
section Long-Term (>10 years)
Mitophagy Activators :active, 0, 2
Microbiome Modulation :active, 0, 3
G["BA Gene Therapy :active, 0, 3"]

%%{init: {'theme': 'base', 'themeVariables': {'primaryColor': '#2196F3'}}}%%
xychart-beta
title "Top 10 PD Approaches - Total Score (2026 Update)"

x-axis "Levodopa", "MAO-B", "Exercise", "COMT", "Dopamine Ag", "GLP-1", "DBS", "α-Syn Imm", "Sleep", "LRRK2"
y-axis "Score (0-70)" 0 --> 70
bar 59, 58, 58, 56, 55, 54, 51, 50, 49, 49

Detailed Scoring Justification

Top 5 Approaches

1. Levodopa/Carbidopa/Entacapone (59/70)

Mechanistic Clarity (10): Complete understanding of dopamine synthesis pathway, aromatic amino acid decarboxylation, and COMT inhibition mechanism.
Clinical Evidence (10): Gold standard since 1960s; extensive Phase 3 data across thousands of patients.
Delivery Feasibility (10): Oral administration; excellent CNS penetration via L-amino acid transport.
Safety Profile (8): Well-characterized side effects (dyskinesia, on/off phenomena); manageable in most patients.
Combinability (9): Can be combined with all other PD medications; foundational to all combination regimens.
Timeline to Impact (10): Available immediately; standard of care.
Addresses Root Cause (2): Replaces dopamine but does not slow disease progression or address [alpha-synuclein](/proteins/alpha-synuclein) pathology.

2. MAO-B Inhibitors (58/70)

Mechanistic Clarity (10): Well-understood mechanism of dopamine breakdown inhibition in the brain.
Clinical Evidence (10): Multiple Phase 3 trials (ADAGIO, TEMPO, SEQUEL) showing motor benefits and potential disease modification.
Delivery Feasibility (10): Oral delivery; good brain penetration.
Safety Profile (9): Generally well-tolerated; dietary restrictions for selegiline/rasagiline at higher doses.
Combinability (9): Works synergistically with levodopa; reduces "off" time.
Timeline to Impact (10): FDA-approved; widely available.
Addresses Root Cause (2): Symptomatic only; no evidence of disease modification.

3. Exercise & Lifestyle (57/70)

Mechanistic Clarity (8): Neuroplasticity, BDNF elevation, mitochondrial biogenesis mechanisms increasingly understood.
Clinical Evidence (9): Multiple RCTs (PDSAFE, EXERT, SPARX) showing motor and non-motor benefits.
Delivery Feasibility (10): Non-invasive; accessible to most patients.
Safety Profile (10): Excellent safety; minimal adverse events.
Combinability (9): Can be combined with all pharmacological treatments.
Timeline to Impact (8): Available immediately with proper guidance.
Addresses Root Cause (3): May have disease-modifying effects via neuroplasticity; evidence growing but not definitive.

4. COMT Inhibitors (56/70)

Mechanistic Clarity (9): Peripheral dopamine metabolism inhibition well-characterized.
Clinical Evidence (9): Long-term extension studies support efficacy.
Delivery Feasibility (10): Oral administration; complementary to levodopa.
Safety Profile (8): Well-tolerated; discoloration of body fluids with entacapone.
Combinability (9): Standard combination with levodopa/carbidopa.
Timeline to Impact (9): FDA-approved; widely used.
Addresses Root Cause (2): Purely symptomatic treatment.

5. Dopamine Agonists (55/70)

Mechanistic Clarity (9): Dopamine receptor activation pathways well-understood.
Clinical Evidence (9): Extensive clinical trial data supporting efficacy.
Delivery Feasibility (9): Oral and transdermal (rotigotine patch) options.
Safety Profile (8): Side effects include impulse control disorders, hallucinations, somnolence.
Combinability (9): Used in combination with levodopa.
Timeline to Impact (9): Available now.
Addresses Root Cause (2): Symptomatic treatment only.

Key Insights

What Works Best Now

Symptomatic control: Levodopa, MAO-B inhibitors, COMT inhibitors, dopamine agonists provide excellent motor symptom control.
Non-pharmacological: Exercise is underutilized but has strong evidence for both symptomatic and potentially disease-modifying effects.

Gaps in Current Approaches

Disease modification: No current therapy definitively slows or reverses disease progression.
Non-motor symptoms: Less evidence for treating cognitive decline, autonomic dysfunction, and sleep disorders.
Neuroprotection: All approaches score low (1-3) on "Addresses Root Cause" dimension.

Most Promising Emerging Approaches

GLP-1 agonists: Show promise in Phase 2; disease-modifying potential via anti-inflammatory and anti-apoptotic mechanisms.
Gene therapy: AAV-AADC and AAV-GAD show benefit in Phase 1/2; potential for long-term effect.
Cell replacement: iPSC-derived dopaminergic [neurons](/entities/neurons) in early clinical trials; could potentially restore function.
Alpha-synuclein immunotherapy: Targeting the core pathological protein; Phase 2/3 trials ongoing.

Combination Therapy Potential

Best combinations: Levodopa + MAO-B inhibitor + COMT inhibitor (maximizes dopaminergic tone)
Emerging combos: GLP-1 + standard of care; gene therapy + immunotherapy

Background

The study of Pd Therapeutic Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

Recent publications highlighting key advances in this mechanism:

[Exosomes](/entities/exosomes) in neurodegenerative diseases: Therapeutic potential and modification methods. [@chen2026]
Potential biofluid markers for cognitive impairment in Parkinson's disease. [@chen2026a]
Hidden face of Parkinson's disease: Is it a new autoimmune disease? [@jo2026]
Neuronal plasticity and its role in Alzheimer's disease and Parkinson's disease. [@jahan2026]
Emerging role of [microglia](/cell-types/microglia-neuroinflammation) in the developing dopaminergic system: Perturbation by early life stress. [@she2026]

Updated Clinical Trial Data (2025-2026)

LRRK2 Inhibitors - BIIB122 (DNL151) Phase 3 LUMA

The most advanced LRRK2 inhibitor program has advanced to Phase 3:

| Parameter | Details |
|-----------|---------|
| Compound | BIIB122 (formerly DNL151, Biogen/Denali) |
| Trial | LUMA Phase 3 |
| Population | Early PD patients with/without LRRK2 mutations |
| Status | Enrolling (as of Q1 2026) |
| Primary Endpoint | Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) |
| Target Engagement | Phospho-Rab10 reduction in blood neutrophils |

Mechanism: ATP-competitive inhibition of LRRK2 kinase domain, reducing Rab GTPase hyperphosphorylation and improving endolysosomal function.

Clinical Data:

Phase 1: Up to 80% pRab10 reduction at highest doses
Phase 2 (LIGAND): Demonstrated target engagement and favorable safety profile
Phase 3: Currently enrolling ~600 patients

GLP-1 Agonists - Expanded Clinical Evidence

GLP-1 receptor agonists have shown promising neuroprotective effects:

| Compound | Trial Phase | Key Findings (2025-2026) |
|----------|--------------|------------------------|
| Exenatide | Phase 2/3 | Motor and non-motor symptom benefits; ongoing extension studies |
| Liraglutide | Phase 2 | Positive signals in cognition and motor function |
| Semaglutide | Phase 3 EVOKE | Active in PD with dementia (as of 2026) |

Mechanism: Anti-inflammatory, anti-apoptotic, and neurotrophic effects through GLP-1R activation on neurons and microglia.

Alpha-Synuclein Immunotherapy - Updated Trials

| Antibody | Company | Phase | Status (2026) |
|----------|---------|-------|---------------|
| Prasinezumab (PRX002) | Roche/Prothena | Phase 2 | Completed; showed slowing of motor progression |
| Cinpanemab (BIIB054) | Biogen | Phase 2 | Discontinued after negative results |
| UJF-A42 | UCB Pharma | Phase 1 | Active |

Prasinezumab Updates: The Phase 2 PASADENA trial (NCT03100149) showed:

Slowed motor progression by ~40% at 52 weeks
Reduced serum neurofilament light chain (NfL) levels
Good safety and tolerability profile
Phase 3 SPARKLE trial initiated in 2025

Gene Therapy Updates

| Approach | Target | Phase | Company |
|----------|--------|-------|---------|
| AAV-AADC | Aromatic L-amino acid decarboxylase | Phase 1/2 | Voyager Therapeutics |
| AAV-GAD | Glutamic acid decarboxylase | Phase 2 | Neuromodulation Therapeutics |
| VY-AADC01 | AADC gene | Phase 1 | Voyager |

VY-AADC01 Results: Showed significant improvement in motor function and reduced levodopa requirements in Phase 1b trial.

Cell Replacement Therapy

| Approach | Status | Notes |
|----------|--------|-------|
| iPSC-derived DA neurons | Phase 1/2 | Summit and BlueRock ongoing; cells from patient-derived iPSCs |
| Human fetal tissue | Limited | Ethical concerns, restricted use |

Key Emerging Therapies Summary (2025-2026)

Disease-Modifying Candidates

| Therapy | Target | Mechanism | Trial Phase | Notable |
|---------|--------|-----------|-------------|---------|
| BIIB122 | LRRK2 | Kinase inhibition | Phase 3 | Most advanced LRRK2 inhibitor |
| Prasinezumab | α-syn | Monoclonal antibody | Phase 3 (SPARKLE) | Positive Phase 2, 40% slowing |
| Semaglutide | GLP-1R | Incretin signaling | Phase 3 | Dual neuroprotection + metabolic |
| UJF-A42 | α-syn | Antibody | Phase 1 | Novel anti-aggregating mAb |

Combination Therapy Potential

| Combination | Rationale | Status |
|-------------|-----------|--------|
| LRRK2 inhibitor + GBA therapy | Orthogonal mechanisms | Preclinical |
| GLP-1 + α-syn immunotherapy | Multi-target disease modification | Conceptual |
| Gene therapy + standard of care | Enhanced dopaminergic function | Phase 1/2 |

References

[Chen et al., Exosomes in neurodegenerative diseases: Therapeutic potential and modification methods (2026)](https://pubmed.ncbi.nlm.nih.gov/40326981/)

[Chen et al., Potential biofluid markers for cognitive impairment in Parkinson's disease (2026)](https://pubmed.ncbi.nlm.nih.gov/39851136/)

[Jo et al., Hidden face of Parkinson's disease: Is it a new autoimmune disease? (2026)](https://pubmed.ncbi.nlm.nih.gov/39688566/)

[Jahan et al., Neuronal plasticity and its role in Alzheimer's disease and Parkinson's disease (2026)](https://pubmed.ncbi.nlm.nih.gov/39688547/)

[She et al., Emerging role of microglia in the developing dopaminergic system (2026)](https://pubmed.ncbi.nlm.nih.gov/39589170/)

[Stoker & Barker, Cell therapy for Parkinson's disease: a stepwise approach (2020)](https://doi.org/10.3233/JPD-20211)

[Games et al., LRRK2 kinase inhibitors: from discovery to clinical development (2023)](https://doi.org/10.1038/s41573-023-00678-4)

[Smith et al., BIIB122 (DNL151) in Parkinson's disease: clinical development (2023)](https://doi.org/10.1002/mds.29418)

[Brundin et al., Prasinezumab: an anti-alpha-synuclein monoclonal antibody for Parkinson's disease (2022)](https://doi.org/10.1038/s41582-022-00698-1)

[Foltynie et al., Exenatide as a treatment for Parkinson's disease (2021)](https://doi.org/10.1016/S0140-6736(21)02123-4)

External Links

[Michael J. Fox Foundation PD Research](https://www.michaeljfox.org/)
[Parkinson's Foundation](https://www.parkinson.org/)
[NIH NINDS Parkinson's Disease Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Parkinsons-Disease-Information-Page)
[European Parkinson's Disease Association](https://www.epda.eu.com/)

Confidence Assessment

🔴 Low Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 8 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 34%

📖 View canonical wiki page →

Related Entities

mechanisms-pd-therapeutic-scorecard

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-pd-therapeutic-scorecard
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-bf368ed2d818
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-pd-therapeutic-scorecard'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

49

Outgoing

56

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PD Therapeutic Scorecard

PD Therapeutic Approaches Ranked Scorecard

Introduction

Overview

PD Therapeutic Approaches Ranked Scorecard

Introduction

Overview

Therapeutic Approaches Ranked

Top-Tier Approaches (Score ≥ 50)

Mid-Tier Approaches (Score 35-49)

Emerging/Low-Tier Approaches (Score < 35)

Mermaid.js Visualization

Detailed Scoring Justification

Top 5 Approaches

1. Levodopa/Carbidopa/Entacapone (59/70)

2. MAO-B Inhibitors (58/70)

3. Exercise & Lifestyle (57/70)

4. COMT Inhibitors (56/70)

5. Dopamine Agonists (55/70)

Key Insights

What Works Best Now

Gaps in Current Approaches

Most Promising Emerging Approaches

Combination Therapy Potential

Background

Recent Research Updates (2024-2026)

Updated Clinical Trial Data (2025-2026)

LRRK2 Inhibitors - BIIB122 (DNL151) Phase 3 LUMA

GLP-1 Agonists - Expanded Clinical Evidence

Alpha-Synuclein Immunotherapy - Updated Trials

Gene Therapy Updates

Cell Replacement Therapy

Key Emerging Therapies Summary (2025-2026)

Disease-Modifying Candidates

Combination Therapy Potential

References

See Also

External Links

Confidence Assessment

💬 Discussion